NALIA Systems is pleased to announce the filing of two new patent applications that highlight the continued development of its technology. NALIA is a developer of state-of-the-art multiplex immunodiagnostic systems for clinical management, biomedical research and drug discovery.
NALIA’s technology uses multi-biomarker panels in the form of miniaturised ELISA-type tests to allow the identification and quantitation of protein and immunological biomarkers. The first of NALIA’s new patent applications covers technology allowing for the detection of both antigen and antibody components simultaneously, a feature unique in multiplex immunodiagnostic systems and which will significantly expand the range of disease tests that NALIA can develop.
The Company’s second patent application covers methods of increasing the sensitivity and assay time using its system as a means to evolve its technology towards Point-of-Care applications. Speed to result is of great importance in this market and traditional ELISA tests are far too slow. NALIA’s original platform technology already allows it to produce results in less than 20 minutes for many markers thus offering the potential to be the first to market with a simple point-of-care, multiplex immunodiagnostic technology.
Using these technologies NALIA is also expanding its business with biopharmaceutical and biotech companies for which it develops custom arrays as well as addressing established multiplex immunodiagnostic challenges in clinical diagnostics.